Ascendis Presents Updated And New TransCon IL-2 β⁄γ Monotherapy And Combination Therapy Data Confirming Clinical Activity Across Tumor Types At ESMO 2023
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma A/S (NASDAQ:ASND) presented updated and new data from its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ at ESMO 2023. The data showed clinical responses with TransCon IL-2 β⁄γ as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy. The company continues enrollment in indication-specific cohorts for Phase 2 portion of the IL-Believe Trial.
October 26, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma's ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ showed promising results, which could potentially boost investor confidence in the company's oncology pipeline.
The positive results from the ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ presented at ESMO 2023 could potentially boost investor confidence in Ascendis Pharma's oncology pipeline. The data showed clinical responses with TransCon IL-2 β⁄γ as monotherapy or in combination with checkpoint inhibitor, which is a positive development for the company. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100